Companies › Rocket Pharmaceuticals
4 active drug programs in 4 registered trials: 2 Phase 1, 2 Phase 2; Cardiovascular, Hematology; next expected readout Jun 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| RP-A501 rAAV9 gene therapy delivering human LAMP2B transgene | LAMP2 | Phase 2 | Danon Disease | Jun 2028 |
| RP-L102 Lentiviral vector-mediated ex vivo gene transfer of FANCA gene into CD34+ hematopoietic st | FANCA | Phase 2 | Fanconi Anemia Complementation Group A | – |
| RP-A601 AAV serotype rh.74 vector encoding human plakophilin 2 (PKP2) | PKP2 | Phase 1 | PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) | Sep 2028 |
| RP-A701 AAV gene therapy delivering BAG3 transgene via AAVrh.74 capsid | BAG3 | Phase 1 | Dilated Cardiomyopathy (DCM) | Jun 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04248439 | RP-L102 | Phase 2 | Fanconi Anemia Complementation Group A | Hematology | May 2026 |
| NCT06092034 | RP-A501 | Phase 2 | Danon Disease | Cardiovascular | Jun 2028 |
| NCT05885412 | RP-A601 | Phase 1 | PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) | Cardiovascular | Sep 2028 |
| NCT07137338 | RP-A701 | Phase 1 | Dilated Cardiomyopathy (DCM) | Cardiovascular | Jun 2029 |
Cash and short-term investments of $284m on 2026-06-30; operating cash outflow about $172m a year; runway about 20 months at that burn, to Feb 2028; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
AstraZeneca Affinia Therapeutics Tenaya Therapeutics Lexeo Therapeutics
Lexeo Therapeutics Nectero Medical Rohto Pharmaceutical Beijing Inno Medicine Kardigan
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.